DNAGO.Ai entered into a definitive business combination agreement to acquire Oncologix Tech, Inc. (OTCPK:OCLG) in a reverse merger transaction on May 2, 2022. Upon consummation of this combination, OCLG will be renamed DNAGO (the "combined company") and its common stock and warrants are expected to remain listed on OTC Market under the ticker symbols OCLG. The combined company will continue DNAGO's operations. Following the successful combination, Frank I Igwealor resigned from the position of President and Chief Executive Officer of OCLG and Madeline Choi was appointed as the new Chief Executive Officer. The combined OCLG and DNAGO Company will be led by Madeline Choi, Chief Executive Officer and her Executive Team of DNAGO.

Transaction is subject to approval by OCLG's and DNAGO 's shareholders and satisfaction, or the waiver of, customary closing conditions identified in the business combination agreement. The transaction has been approved by each of OCLG's and DNAGO 's Boards of Directors. Transaction is expected to be completed in the second quarter of 2022. Alpha Advocate Law Group PC acted as legal advisor to Oncologix Tech, Inc.